CA
IDXG

Calton & Associates’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Calton & Associates’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-300
Closed -$3K – 1436
2017
Q4 		$3K Buy
+300
New +$3.63K ﹤0.01% 1373

Other funds holding IDXG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LCC
Lincoln Capital Corp East Greenwich, Rhode Island $308M AUM 24.88% 1-Year Est. Return

Calton & Associates's IDXG Position: Q1 2018 in Review

Calton & Associates sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2018, closing a stake of 300 shares — an estimated $3K sold.

Calton & Associates first reported a position in IDXG in Q4 2017 and held it in 1 quarter. The position peaked at $3K in Q4 2017. 14 funds tracked by Wall St. Rank hold IDXG as of Q1 2018.

  • Calton & Associates reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Calton & Associates sold 300 Interpace Biosciences, Inc. Common Stock shares in Q1 2018, an estimated $3K.
  • Calton & Associates first reported a position in Interpace Biosciences, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Calton & Associates's Interpace Biosciences, Inc. Common Stock position peaked at $3K in Q4 2017.
  • 14 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.